Ying Gue

Dr. Ying Gue

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in European Heart Journal
Verified
Journal Article
Closed access
MFMohamed Farag
Mohamed Farag
NSNikolaos Spinthakis
Nikolaos Spinthakis
YGYing Gue
Ying Gue
MSManivannan Srinivasan
Manivannan Srinivasan
KSKeith Sullivan
Keith Sullivan
DGDiana A Gorog
Diana A Gorog
The endogenous fibrinolytic system serves to prevent lasting thrombotic occlusion and infarction following initiation of coronary thrombosis. We aimed to determine whether impaired endogenous fibrinolysis can identify patients with ST-segment elevation myocardial infarction (STEMI) who remain at high cardiovascular risk despite dual antiplatelet therapy (DAPT). A prospective, observational study was conducted in 496 patients presenting with STEMI for primary percutaneous coronary intervention (PPCI). Blood was tested on arrival pre-PPCI, at discharge and at 30 days to assess thrombotic status using the automated point-of-care global thrombosis test and patients followed for 1 year for major adverse cardiovascular events (MACEs). Endogenous fibrinolysis was significantly impaired [baseline lysis time (LT) ≥2500 s] in 14% of patients and was highly predictive of recurrent MACE [hazard ratio (HR) 9.1, 95% confidence interval (CI) 5.29-15.75; P < 0.001], driven by cardiovascular death (HR 18.5, 95% CI 7.69-44.31; P < 0.001) and myocardial infarction (HR 6.2, 95% CI 2.64-14.73; P < 0.001), particularly within 30 days. Fibrinolysis remained strongly predictive of MACE after adjustment for conventional risk factors (HR 8.03, 95% CI 4.28-15.03; P < 0.001). Net reclassification showed that adding impaired fibrinolysis improved the prediction of recurrent MACE by >50% (P < 0.001). Patients with spontaneous ST-segment resolution pre-PPCI had more rapid, effective fibrinolysis [LT 1050 (1004-1125) s vs. 1501 (1239-1997) s, P < 0.001] than those without. Lysis time was not altered by standard of care STEMI treatment including DAPT and was unchanged at 30 days. Endogenous fibrinolysis assessment can identify patients with STEMI who remain at very high cardiovascular risk despite PPCI and DAPT. Further studies are needed to assess whether these patients may benefit from additional, personalized antithrombotic/anticoagulant medication to reduce future cardiovascular risk. http://www.clinicaltrials.gov. Unique identifier: NCT02562690.

22 March 2022 in EP Europace
Verified
Journal Article
Closed access
DGDiana Gorog
Diana Gorog
YGYing Gue
Ying Gue
TCTze-Fan Chao
Tze-Fan Chao
LFLaurent Fauchier
Laurent Fauchier
JFJose Luis Ferreiro
Jose Luis Ferreiro
Gregory LipGregory Lip
Gregory Lip
Whilst there is a clear clinical benefit of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially intracranial bleeds) may still occur and be devastating. The decision to initiate and continue anticoagulation is often based on a careful assessment of both the thromboembolism and bleeding risk. The more common and validated bleeding risk factors have been used to formulate bleeding risk stratification scores, but thromboembolism and bleeding risk factors often overlap. Also, many factors that increase bleeding risk are transient and modifiable, such as variable international normalized ratio values, surgical procedures, vascular procedures, or drug–drug and food–drug interactions. Bleeding risk is also not a static ‘one off’ assessment based on baseline factors but is dynamic, being influenced by ageing, incident comorbidities, and drug therapies. In this Consensus Document, we comprehensively review the published evidence and propose a consensus on bleeding risk assessments in patients with AF and VTE, with the view to summarizing ‘best practice’ when approaching antithrombotic therapy in these patients. We address the epidemiology and size of the problem of bleeding risk in AF and VTE, review established bleeding risk factors, and summarize definitions of bleeding. Patient values and preferences, balancing the risk of bleeding against thromboembolism are reviewed, and the prognostic implications of bleeding are discussed. We propose consensus statements that may help to define evidence gaps and assist in everyday clinical practice.

1 April 2021 in American Heart Journal
Verified
Journal Article
Closed access
YGYing Gue
Ying Gue
KAKrishma Adatia
Krishma Adatia
RKRahim Kanji
Rahim Kanji
TPTatjana Potpara
Tatjana Potpara
GLGregory Y.H. Lip
Gregory Y.H. Lip
DGDiana Gorog
Diana Gorog

1 November 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
YGYing Gue
Ying Gue
MSMax Sayers
Max Sayers
BWBenjamin T. Whitby
Benjamin T. Whitby
RKRahim Kanji
Rahim Kanji
KAKrishma Adatia
Krishma Adatia
DGDiana Gorog
Diana Gorog

1 November 2022 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
Gregory LipGregory Lip
Gregory Lip
YGYing Gue
Ying Gue
JZJuqian Zhang
Juqian Zhang
TCTze-Fan Chao
Tze-Fan Chao
HCHugh Calkins
Hugh Calkins
TPTatjana Potpara
Tatjana Potpara

25 June 2019 in EP Europace
Verified
Journal Article
Open access
PDF file
NSNikolaos Spinthakis
Nikolaos Spinthakis
YGYing Gue
Ying Gue
MFMohamed Farag
Mohamed Farag
MSManivannan Srinivasan
Manivannan Srinivasan
DWDavid Wellsted
David Wellsted
DGDiana Gorog
Diana Gorog
Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is unknown. Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular atrial fibrillation (NVAF). In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in NVAF patients (n = 180) taking aspirin, warfarin, or apixaban. In a prospective longitudinal study, patients were tested before and after apixaban (n = 80). Endogenous fibrinolysis was assessed using the Global Thrombosis Test (GTT) and thromboelastography (TEG). Endogenous fibrinolysis [measured by GTT lysis time (LT)] was shorter on apixaban compared with warfarin or aspirin [median 1850 (IQR 1591–2300) vs. 2758 (2014–3502) vs. 2135 (1752–2463) s, P < 0.0001]. Among TEG indices, a small but significant difference in clot lysis time (CLT) was observed [apixaban 60.0 (45.0–61.0) vs. warfarin 61.0 (57.0–62.0) vs. aspirin 61.0 (59.0–61.0) min, P = 0.036]. Apixaban improved endogenous fibrinolysis measured using the GTT [LT pre-treatment 2204 (1779–2738) vs. on-treatment 1882 (1607–2374) s, P = 0.0003], but not by using TEG. Change in LT (ΔLT) with apixaban correlated with baseline LT (r = 0.77, P < 0.0001). There was weak correlation between ΔLT and ΔCLT in response to apixaban (r = 0.28, P = 0.02) and between on-apixaban LT and CLT (r = 0.25, P = 0.022). Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.